Consistent with our findings, endogenous expression of SMYD3 was also reported to be significantly up-regulated in a majority of colorectal carcinoma, hepatocellular carcinoma, prostate cancer, and breast cancer specimens [15, 26, 41]. This evidence concerns the gene SMYD3 and prostate carcinoma.